Boundless Bio (BOLD) 10% Owner Kevin Tang Buys $277K of Stock

By TradeTexts Research Desk Oct 20, 2026, 6:02 PM EDT

Key Points

10% owner Kevin Tang bought 118,185 shares of Boundless Bio, Inc. (BOLD) on October 16, 2026, at $2.34 per share for a total value of $276,552.90.
The transaction grew Tang's total stake in the clinical-stage oncology company to 2,958,820 shares, according to a Form 4 filing with the SEC.
Boundless Bio is developing treatments for oncogene amplified cancers and recently traded around $2.43 per share.

Since the trade, $BOLD is up 3.9% to date (from the $2.34 close on Oct 16, 2026).

Get Boundless Bio text alerts

We text you when insiders, Congress, analysts or big funds move on $BOLD.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boundless Bio, Inc. alert may contain errors. Disclosures

On October 16, 2026, 10% owner Kevin Tang purchased 118,185 shares of Boundless Bio, Inc. (BOLD). According to a Form 4 filed with the Securities and Exchange Commission, the shares were bought at a price of $2.34 each, totaling $276,552.90.

BOLD Boundless Bio, Inc.

$2.43 +99.18% year to date

Daily close · Oct 20, 2026

Insider trading track record

Kevin Tang vs. the S&P 500

YTD return +3.96% hypothetical

All-time return +19.04% S&P 500 +11.50%

vs. S&P 500 +7.54% ahead of the index

Hypothetical returns from Kevin Tang's disclosed trades, not real profit or advice. How we model this.

Inside Kevin Tang's Boundless Bio Trade

Tang bought the shares on October 16, 2026, through an open market transaction. The purchase lifted his total holdings to 2,958,820 shares. This move follows an earlier purchase by Tang on June 25, 2026, and marks another addition to his position in the biotechnology firm this year.

Other Institutional Activity in Boundless Bio

Other major funds hold stakes in Boundless Bio. Arch Venture Management, Llc held 2,694,095 shares worth $6,546,651 after growing its holdings by 1,347,048 shares. Tang Capital Management, LLC held 2,559,875 shares valued at $6,220,496 following an increase of 1,279,938 shares. Adar1 Capital Management, LLC added 984,108 shares to end with 1,968,216 shares worth $4,782,765. Cormorant Asset Management, LP grew its stake by 500,000 shares to reach 1,000,000 shares valued at $2,430,000. Millennium Management Llc increased its position by 378,764 shares, finishing with 478,639 shares worth $1,163,092.

Boundless Bio, Inc. Stock Up 5.2%

Boundless Bio shares closed at $2.34 on the day of the trade. The stock recently traded around $2.43 on October 20, 2026, which is up about 3.8% from the event-day close. The shares sit below their 50-day moving average of $2.73 and above their 200-day moving average of $1.86.

Recent Earnings

Boundless Bio is a clinical-stage oncology company that is not yet profitable, reporting a trailing twelve-month earnings per share loss of $2.85. The firm carries a market capitalization of roughly $56.2 million.

Insider Buying and Selling at Boundless Bio, Inc.

Insiders have been active in the stock throughout the year. Earlier transactions included purchases by Jonathan Lim, Nancy Whiting, Jennifer Lew, and Kevin Tang himself.

About Boundless Bio, Inc.

Boundless Bio is a San Diego-based biotechnology company focused on oncology. The firm develops targeted treatments designed for patients suffering from oncogene amplified cancers by addressing extrachromosomal DNA.

Bottom Line

Investors tracking Boundless Bio can watch for upcoming financial reports and further Form 4 filings to see how insider and institutional positions evolve. This trade simply records a major owner adding to his existing stake.